KYNTRA BIO, INC. 10-Q

ITEM 5. OTHER INFORMATION. Rule 10b5-1 Trading Arrangements None. 82 Table of Contents ITEM 6. E XHIBITS Exhibit Incorporation By Reference Number Exhibit Description Form SEC File No. Exhibit Filing Date 3.1 Amended and Restated Certificate of Incorporation of FibroGen, Inc. 8-K 001-36740 3.1 11/21/2014 3.2 Amended and Restated Bylaws of FibroGen, Inc. S-1/A 333-199069 3.4 10/23/2014 4.1 Form of Common Stock Certificate. 8-K 001-36740 4.1 11/21/2014 4.2 Common Stock Purchase Agreement by and between FibroGen, Inc. and AstraZeneca AB, dated as of October 20, 2014. S-1/A 333-199069 4.17 10/24/2014 10.1 FibroGen, Inc. 2024 Equity Incentive Plan . 8-K 001-36740 10.1 6/7/2024 10.2*† First Amended and Restated Evaluation Agreement by and between FibroGen, Inc. and Fortis Therapeutics, Inc., dated June 6, 2024. — — — — 10.3*† First Amended and Restated Option Agreement and Plan of Merger by and among FibroGen, Inc., Fortis Therapeutics, Inc. and Shareholder Representative Services LLC, as Sellers’ Representative, dated June 6, 2024. — — — — 10.4* Form of Restricted Stock Unit Grant Notice and Award Agreement . — — — — 10.5* Form of Stock Option Grant Notice and Option Agreement . — — — — 31.1* Certification of Chief Executive Officer, as required by Rule 13a-14(a) or Rule 15d-14(a). — — — — 31.2* Certification of Chief Financial Officer, as required by Rule 13a-14(a) or Rule 15d-14(a). — — — — 32.1* Certification of Principal Executive Officer and Principal Financial Officer, as required by Rule 13a-14(b) or Rule 15d-14(b) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. §1350)(1)). — — — — 101.INS Inline XBRL Instance Document: the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. — — — — 101.SCH Inline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents. — — — — 104 Cover Page formatted as inline XBRL and contained in Exhibits 101. — — — — * Filed herewith. † Portions of this exhibit (indicated by asterisks) have been omitted as the Company has determined that (i) the omitted information is not material and (ii) the omitted information would likely cause competitive harm if publicly disclosed or is the type of information the Company treats as confidential. + Indicates a management contract or compensatory plan. 83 Table of Contents SIGNAT URES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. FibroGen, Inc. Date: August 6, 2024 By: /s/ Thane Wettig Thane Wettig Chief Executive Officer (Principal Executive Officer) Date: August 6, 2024 By: /s/ Juan Graham Juan Graham Senior Vice President and Chief Financial Officer (Principal Financial and Accounting Officer) 84